EC Nutrition

Background: This systematic review evaluated primary research to establish blood omega-3 polyunsaturated fatty acids (n-3 PUFA); eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and omega-6 polyunsaturated fatty acids (n-6 PUFA); arachidonic acid (AA) concentration. The effectiveness of their supplementation on clinical and nutritional outcomes and associations between their concentration and clinical and nutritional outcomes were also evaluated.         

Methods: Electronic databases were searched (no restriction-Dec 2018) with no language restrictions. We included studies of cancer patients aged < 18 years and reporting supplementation and/or concentration of EPA, DHA and AA. Evidence was critically appraised employing the CASP tool.

Findings: Three studies (n = 84) met the inclusion criteria, mainly of weak quality and heterogeneous in both study designs and outcomes measured. The overall median(range) n-3 and n-6 PUFA concentration were; EPA: 0.4 (0.24 - 0.4%), DHA: 1.66 (1.3 - 1.68%), AA: 7.01 (6.5 - 7.3%) and AA/EPA: 18.7 (171 - 29.2%). EPA%, DHA% and AA% were all lower than the references 0.45 - 0.77%, 2.22 - 3.76% and 7.91 - 10.46% respectively, whilst AA/EPA% was higher than the reference (< 14.59%). Both higher intake and blood concentration of EPA and DHA may reduce weight loss during initial treatment, whilst a high ratio of AA/EPA may be associated with lower BMI centiles.

Interpretation: EPA and DHA may be beneficial in children with cancer. High-quality population-based longitudinal cohort studies and clinical trials are urgently warranted.

Keywords: Childhood Cancer; N-3 PUFA; N-6 PUFA

1. Herbst RS., et al. “Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology”. Journal of Clinical Oncology 1 (2006): 190-205.
2. Sala A., et al. “Children, cancer, and nutrition--A dynamic triangle in review”. Cancer4 (2004): 677-687.
3. Revuelta Iniesta R., et al. “Nutritional status of children and adolescents with cancer in Scotland: A prospective cohort study”. Clinical Nutrition ESPEN 32 (2019): 96-106.
4. Revuelta Iniesta R., et al. “Effects of pediatric cancer and its treatment on nutritional status: a systematic review”. Nutrition Reviews 5 (2015): 276-295.
5. Brinksma A., et al. “Malnutrition in childhood cancer patients: a review on its prevalence and possible causes”. Critical Reviews in Oncology and Hematology 2 (2012):249-275.
6. Bayram I., et al. “The use of a protein and energy dense eicosapentaenoic acid containing supplement for malignancy-related weight loss in children”. Pediatrics and Blood Cancer5 (2009): 571-574.
7. Endres S., et al. “The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells”. The New England Journal of Medicine 5 (1989): 265-271.
8. Gogos CA., et al. “Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy: a randomized control trial”. Cancer2 (1998): 395-402.
9. van der Meij BS., et al. “PUFAs in cancer, surgery, and critical care: a systematic review on clinical effects, incorporation, and washout of oral or enteral compared with parenteral supplementation”. The American Journal of Clinical Nutrition 5 (2011):1248-1265.
10. Lorente-Cebrián S., et al. “Role of omega-3 fatty acids in obesity, metabolic syndrome, and cardiovascular diseases: a review of the evidence”. Journal of Physiology and Biochemistry 3 (2013): 633-651.
11. Gleissman H., et al. “Omega-3 fatty acid supplementation delays the progression of neuroblastoma in vivo”. International Journal of Cancer 7 (2011):1703-1711.
12. Larsson SC., et al. “Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms”. The American Journal of Clinical Nutrition 6 (2004): 935-945.
13. Greene ER., et al. “Regulation of inflammation in cancer by eicosanoids”. Prostaglandins and Other Lipid Mediators 1-4 (2011): 27-36.
14. Marra CA., et al. “Modulation of delta 6 and delta 5 rat liver microsomal desaturase activities by dexamethasone-induced factor”. Biochimica et Biophysica Acta 3 (1986): 388-393.
15. Calder PC. “Omega-3 fatty acids and inflammatory processes”. Nutrients3 (2010): 355-374.
16. Peckett AJ., et al. “The effects of glucocorticoids on adipose tissue lipid metabolism”. Metabolism 11 (2011): 1500-1510.
17. Wallace WHB., et al. “Long term follow-up of survivors of childhood cancer: summary of updated SIGN guidance”. BMJ 346 (2013): f1190-f1190.
18. Swanson D., et al. “Omega-3 fatty acids EPA and DHA: health benefits throughout life”. Advances in Nutrition 1 (2012): 1-7.
19. Moher D., et al. “Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement”. Journal of Clinical Epidemiology 10 (2009): 1006-1012.
20. Steliarova-Foucher E., et al. “International Classification of Childhood Cancer, third edition”. Cancer7 (2005): 1457-1467.
21. Damsgaard CT., et al. “Eicosapentaenoic acid and docosahexaenoic acid in whole blood are differentially and sex-specifically associated with cardiometabolic risk markers in 8-11-year-old danish children”. PLoS One10 (2014): e109368-e109368.
22. Revuelta Iniesta R., et al. “Assessment of Plasma Antioxidants, Oxidative Stress and Polyunsaturated Fatty Acids in Paediatric Cancer Patients: A Prospective Cohort Study”. EC Nutrition4 (2015): 412-425.
23. de la Torre Aguilar MJ., et al. “Plasma fatty acids profile in paediatric cancer patients”. Nutrición Hospitalaria 2 (2012):617-622.
24. Hibbeln JR., et al. “Healthy intakes of n-3 and n-6 fatty acids: estimations considering worldwide diversity”. The American Journal of Clinical Nutrition 6 (2006):1483S-1493S.
25. Kris-Etherton P., et al. “Position of the American Dietetic Association and Dietitians of Canada: dietary fatty acids”. Journal of the American Dietetic Association 9 (2007):1599-1611.
26. Fearon KCH., et al. “Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial”. Gut 10 (2003):1479-1486.
27. Gogos CA., et al. “The effect of dietary omega-3 polyunsaturated fatty acids on T-lymphocyte subsets of patients with solid tumors”. Cancer Detection and Prevention 5 (1995): 415-417.
28. Mosconi C., et al. “Decrease of polyunsaturated fatty acids and elevation of the oleic/stearic acid ratio in plasma and red blood cell lipids of malnourished cancer patients”. JPEN Journal of Parenteral and Enteral Nutrition 5 (1989): 501-504.
29. Brinksma A., et al. “Changes in nutritional status in childhood cancer patients: A prospective cohort study”. Clinical Nutrition 1 (2015): 66-73.
30. Burrows TL., et al. “A systematic review of the validity of dietary assessment methods in children when compared with the method of doubly labeled water”. Journal of the American Dietetic Association 10 (2010): 1501-1510.
31. Kelly KM., et al. “Variations in energy and nutrient specific consumption over the course of therapy in children with acute lymphoblastic leukemia”. Blood 120,21 (2012): 2575.
32. Zhang FF., et al. “Low Levels of Energy Expenditure in Childhood Cancer Survivors: Implications for Obesity Prevention”. Journal of Pediatric Hematology Oncology 3 (2015): 232-236.
33. Pappalardo G., et al. “Eicosapentaenoic acid in cancer improves body composition and modulates metabolism”. Nutrition4 (2015): 549-555.
34. Murphy AJ., et al. “Body composition of children with cancer during treatment and in survivorship”. The American Journal of Clinical Nutrition4 (2015): 891-896.